Medicenna Therapeutics (TSE:MDNA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Medicenna Therapeutics is set to present at the 2024 ASCO Annual Meeting, showcasing new data from their ABILITY-1 Study on MDNA11, an innovative immunotherapy for solid tumors, and comparing survival outcomes of bizaxofusp against a control arm for recurrent glioblastoma. Their presentations will highlight MDNA11’s potential in monotherapy and in combination with pembrolizumab, and bizaxofusp’s performance in Phase 2 trials for a lethal brain cancer.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
